NEW YORK CITY (dpa-AFX) - While reporting financial results for the third quarter on Thursday, Bristol-Myers Squibb Co. (BMY) slashed its earnings guidance for the full-year 2026, while raising annual revenue outlook.
For fiscal 2026, the company now projects earnings in a range of about $6.35 to $6.55 per share on worldwide total revenues between about $49.75 billion and $50.25 billion.
The company noted that the guidance includes a $0.60 per share net impact from Acquired IPRD charges and licensing income.
Previously, the company expected earnings in the range of about $6.75 to $7.00 per share on worldwide total revenues between about $49.0 billion and $50.0 billion.
The company also said it continues to expect total Worldwide Eliquis revenues to increase in 2026, when compared to 2025 by 20 to 25 percent.
In Thursday's pre-market trading, BMY is trading on the NYSE at $61.94, up $1.33 or 2.19 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
